Tesamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
single-nucleotide polymorphism (SNP) Any substitution of a single nucleotide which occurs at a specific position within a genome and with measurable frequency within a population; for example, at a specific base position in a DNA sequence, the majority of the individuals in a population may have a cytosine (C), while in a minority of individuals, the same position may be occupied by an adenine (A). SNPs are usually defined with respect to a "standard" reference genome; an individual human genome differs from the reference human genome at an average of 4 to 5 million positions, most of which consist of SNPs and short indels. See also polymorphism.
== Inhibition of glycolytic pathway == The impairment of glucose metabolism by fatty acid oxidation is mediated by the short-term inhibition of several glycolytic processes. The extent of inhibition increases along the glycolytic pathway, being most severe at the level of pyruvate dehydrogenase and less severe at the level of glucose uptake and 6-phosphofructo-1-kinase (PFK-1). This sequence occurs because of the initial event, triggered by fatty acid oxidation, is an increase in the mitochondrial ratios of [acetyl-CoA]/[CoA] and [NADH]/[NAD+]. These both serve to inhibit pyruvate dehydrogenase activity. It has been proposed that these changes lead to an accumulation of cytosolic citrate, which in turn inhibits PFK-1, followed by an increase in glucose 6-phosphate, which eventually inhibits hexokinase.
=== Myomesin 3 === Myomesin 3 is the least researched in the myomesin class due to it being the most recently discovered. It is encoded by the MYOM3 gene. It is located in the M6/M6' lines of the M-band and is expressed in intermediate skeletal muscles and adult cardiac muscles (specifically in the left ventricle and left atrium). MYOM3 is especially expressed in neonatal skeletal muscles, extraocular muscles, slow muscles, and IIA skeletal fibers. Myomesin 3 is the only member of the myomesin protein family to be completely absent from cardiac expression. Myomesin 3 displays an inverse relationship with myomesin 2.
Cancer begins as cells that grow uncontrollably, usually as a result of an internal change or oncogenic mutations within the cell. Cancer develops and progresses as the microenvironment undergoes dynamic changes. The stromal reaction in cancer is similar to the stromal reaction induced by injury or wound repair: increased extracellular matrix (ECM) and growth factor production and secretion, which consequently cause growth of the tissue. In other words, the body reacts similarly to a cancer as it does to a wound, causing scar-like tissue to be built around the cancer. As such, the surrounding stroma plays a very important role in the progression of cancer. The interaction between cancer cells and surrounding tumor stroma is thus bidirectional, and the mutual cellular support allows for the progression of the malignancy.
Sources: en.wikipedia.org
Between 1815 and 1824, the Rev William Buckland, the first Reader of Geology at the University of Oxford, collected more fossilized bones of Megalosaurus and became the first person to describe a non-avian dinosaur in a scientific journal. The second non-avian dinosaur genus to be identified, Iguanodon, was purportedly discovered in 1822 by Mary Ann Mantell, the wife of English geologist Gideon Mantell, though this is disputed and some historians say Gideon had acquired remains years earlier. Gideon Mantell recognized similarities between his fossils and the bones of modern iguanas and published his findings in 1825. The study of these "great fossil lizards" soon became of great interest to European and American scientists. Owen recognized that the remains that had been found so far, Iguanodon, Megalosaurus and Hylaeosaurus, shared distinctive features, and so decided to present them as a distinct taxonomic group. As clarified by British geologist and historian Hugh Torrens, Owen had given a presentation about fossil reptiles to the British Association for the Advancement of Science in 1841, but reports of the time show that Owen did not mention the word "dinosaur", nor recognize dinosaurs as a distinct group of reptiles in his address. He introduced the Dinosauria only in the revised text version of his talk published in April 1842. With the backing of Prince Albert, the husband of Queen Victoria, Owen established the Natural History Museum, London, to display the national collection of dinosaur fossils and other biological and geological exhibits.
A sector-type mass analyzer uses a static electric and/or magnetic field to control the path of the ion beam. The most common type uses a magnetic field. In a simplified case, the field is a constant field
Cuprates are layered materials, consisting of superconducting planes of copper oxide, separated by layers containing ions such as lanthanum, barium, strontium, which act as a charge reservoir, doping electrons or holes into the copper-oxide planes. Thus the structure is described as a superlattice of superconducting CuO2 layers separated by spacer layers, resulting in a structure often closely related to the perovskite structure. Superconductivity takes place within the copper-oxide (CuO2) sheets, with only weak coupling between adjacent CuO2 planes, making the properties close to that of a two-dimensional material. Electrical currents flow within the CuO2 sheets, resulting in a large anisotropy in normal conducting and superconducting properties, with a much higher conductivity parallel to the CuO2 plane than in the perpendicular direction. Critical superconducting temperatures depend on the chemical compositions, cations substitutions and oxygen content. Chemical formulae of superconducting materials generally contain fractional numbers to describe the doping required for superconductivity. There are several families of cuprate superconductors which can be categorized by the elements they contain and the number of adjacent copper-oxide layers in each superconducting block. For example, YBCO and BSCCO can alternatively be referred to as Y123 and Bi2201/Bi2212/Bi2223 depending on the number of layers in each superconducting block (n).
== See also == Isotope List of elements by stability of isotopes List of nuclides (sorted by half-life) Table of nuclides Alpha nuclide Monoisotopic element Mononuclidic element Primordial element Radionuclide Hypernucleus
=== Production area === India is the largest producer of moringa, with an annual production of 1.2 million tonnes of fruit from an area of 380 km2 (150 sq mi). Among Indian states, Tamil Nadu leads in cultivation area followed by Andhra Pradesh and Karnataka. Moringa is grown in home gardens and as living fences in South and Southeast Asia, where it is commonly sold in local markets. In the Philippines and Indonesia, it is commonly grown for its leaves, which are used as food. Moringa is also actively cultivated by the World Vegetable Center in Taiwan, a center for vegetable research. More generally, moringa grows in the wild or is cultivated in Central America and the Caribbean, northern countries of South America, Africa, South and Southeast Asia, and various countries of Oceania. As of 2010, cultivation in Hawaii was in the early stages for commercial distribution in the US.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。